ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir
London (ots/PRNewswire) - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the 41 week phase IIa ECLAIR study, which evaluated the safety, tolerability, dosing and satisfaction with the ...